Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

The Management of Heparin-induced Thrombocytopenia with Thrombosis That Developed after Aortic Dissection Surgery

대동맥 박리증 수술 후 발생한 혈전증을 동반한 헤파린 기인성 혈소판 감소증의 치료

  • Kim, Jae-Bum (Department of Thoracic and Cardiovascular Surgery, College of Medicine, Keimyung University) ;
  • Park, Nam-Hee (Department of Thoracic and Cardiovascular Surgery, College of Medicine, Keimyung University) ;
  • Choi, Sae-Young (Department of Thoracic and Cardiovascular Surgery, College of Medicine, Keimyung University)
  • 김재범 (계명대학교 의과대학 동산의료원 흉부외과학교실) ;
  • 박남희 (계명대학교 의과대학 동산의료원 흉부외과학교실) ;
  • 최세영 (계명대학교 의과대학 동산의료원 흉부외과학교실)
  • Received : 2010.04.20
  • Accepted : 2010.06.15
  • Published : 2010.10.05
Download PDF
⟨ Previous Next ⟩

Abstract

Heparin-induced thrombocytopenia (HIT) is a clinicopathologic condition and adverse drug reaction caused by immunoglobulin G (IgG) antibodies directed against the heparin-platelet factor 4 complex. HIT with thrombosis (HITT) could lead to limb amputation, stroke, myocardial infarction, and death. We report on the successful management of a HITT patient with argatroban therapy.

헤파린 기인성 혈소판 감소증은 헤파린과 혈소판 제4인자 사이의 복합체에 대항하여 만들어진 면역글로불린-G 항체에 의해 발생한 약물 부작용이라고 할 수 있다. 혈전증을 동반한 헤파린 기인성 혈소판 감소증은 사지 절단이나 뇌졸증, 심근경색과 같은 병을 일으켜 사망에 이르게 할 수 있다. 저자들은 혈전증을 동반한 혈소판 감소증을 agatroban을 사용하여 성공적으로 치료하여 보고하는 바이다.

Keywords

References

  1. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 Suppl):311S-7S.
  2. Ban-Hoefen M, Francis C. Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital. Thromb Res 2009;124:189-92. Epub 2009 Feb 4. https://doi.org/10.1016/j.thromres.2009.01.006
  3. Refaai MA, Van Cott EM, Laposata M. The timing of a positive test result for heparin-induced thrombocytopenia relative to the platelet count and anticoagulant therapy in 43 consecutive cases. Am J Clin Pathol 2003;119:497-504. https://doi.org/10.1309/KM2Y9H9TP6DA59MT
  4. Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2:148-57.
  5. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29. https://doi.org/10.1592/phco.20.4.318.34881
  6. Levine RL, Hursting MJ, David McCollum MS. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006;129;1167-75. https://doi.org/10.1378/chest.129.5.1167
  7. Lubenow N, Selleng S, Wollert HG, Eichler P, Mullejans B, Greinacher A. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg 2003;75:577-9. https://doi.org/10.1016/S0003-4975(02)04309-6
  8. Martin ME, Kloecker GH, Laber DA. Argatroban for anticoagulation during cardiac surgery. Eur J Haematol 2007;78: 161-6.